Although c-Myc has been shown to be a key target for sensitivity to other HDAC inhibitors in various cancers [12–15], it is still unclear whether absolute transcriptional or genomic levels of c-Myc (hereafter, Myc) predict sensitivity to all HDAC inhibitors. This evidence concerns the gene HDAC9 and cancer.